Completed NA INTERVENTIONAL 4-arm NCT05359341

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Comparative Study of DPP-4 Inhibitors and SGLT-2 Inhibitors in Egyptian Diabetic Patients

Sponsor: Beni-Suef University

Interventions Empagliflozin 12.5 MG Empagliflozin 12.5 MG + Sitagliptin 50 mg Sitagliptin 50 mg Sitagliptin 50 mg + Empagliflozin 12.5 MG

Updated 3 times since 2022 Last updated: Apr 27, 2022 Started: Sep 20, 2020 Primary completion: Sep 20, 2021 Completion: Jan 10, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Diabete Type 2 and is currently completed. Beni-Suef University leads this study, which shows 3 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2022 — Jul 2024 [monthly]

Completed NA

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beni-Suef University
Sadat City University

Data source: Sadat City University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• El Sadat, Egypt